It's knee jerk reaction to the bad quarter. No way you can spin it. It may persist for a few days to shake out the folks giving up, the margin (although it looks like last time there really wasn't any margin selling) and anyone who was trying to trade quarterly news flow. No different to the upwards knee jerk reactions on good news. Neither is usually correct.
But you have to say, the stock price had been discounting and foreshadowing a mediocre growth outlook for their drugs for a while now. It was fairly right regardless of how we interpret things here. A shame that Bloomberg is frankly so horribly wrong and doesn't fact check their data I do agree the company should have let that be known if they also knew that. Not good at all and shame on them Maybe they only noticed it this quarter as I would guess SPCEO brought up that number to them before and maybe it was close to the truth It's only this quarter where the disconnect happened Still, I fault them for not rectifying that misperception
There's something of value with the drugs they have as they don't lose money and growth should bounce back. I'd like to think they can still get to 1500- 2000 like they say. That's still pretty low penetration rate. So maybe it's ultimately worth $4-5 bucks in value. But SPCEOs right, any new analyst isn't going to really care given the growth potential of Egrifta. It's just a nice source of positive and growing cash flow to pay all the bills and grow cash a bit. For any new analyst it will be looking like a real bargain once you stack it up to the only other 3-4 companies at or close to a phase 3. You just have to have the non emotional guts to stick with it until you see some of that coverage happen. I would guess anyone attending the R&D day may have a much better sense of how that is going by the kinds of questions being asked, the level of disclosures and the general buzz, if any. That may be the first day in the new life of Th as a development co addressing two much, much larger markets.